Form 4: Acrivon Therapeutics CEO Reports Tax Withholding Transaction
SEC Form 4 Filing
Peter Blume-Jensen, CEO of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On May 14, 2024, Peter Blume-Jensen, the President and CEO of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on SEC Form 4.
- The transaction involved the withholding of 54,918 shares of common stock by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units at a price of $8.36.
- Following the transaction, Blume-Jensen directly owns 2,561,894 shares of Acrivon Therapeutics common stock.
- Additionally, Blume-Jensen indirectly owns 317,736 shares through his spouse, Kristina Masson, co-founder and EVP, but disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to tax withholding, and does not contain information that would significantly impact investor sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors regarding changes in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of transaction: Shares withheld for tax obligations. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.